Skip to main content
SAM CHUN DANG PHARM CO. LTD logo

SAM CHUN DANG PHARM CO. LTD — Investor Relations & Filings

Ticker · 000250 ISIN · KR7000250001 KO Manufacturing
Open in API
Filings indexed 224 across all filing types
Latest filing 2020-02-26 Proxy Solicitation & In…
Country KR South Korea
Listing KO 000250

About SAM CHUN DANG PHARM CO. LTD

http://www.scd.co.kr/english/scd/index.…

SAM CHUN DANG PHARM CO. LTD. is a pharmaceutical company focused on the development, manufacturing, and sale of medications. The company specializes in ophthalmic products, establishing itself as a significant player in the generic eye care market. Its portfolio also extends to other therapeutic areas, including antibiotics and medications for the circulatory system. The company produces a range of ethical (prescription) and over-the-counter (OTC) drugs in both sterile and non-sterile forms. Manufacturing operations adhere to international quality standards, holding both US and EU Good Manufacturing Practice (GMP) certifications.

Recent filings

Filing Released Lang Actions
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a 'Proxy Solicitation' (위임권유) filed by Samchundang Pharm Co., Ltd. It contains information regarding the upcoming Annual General Meeting (AGM), including the purpose of the meeting, details on the proxy solicitation, and financial statements (balance sheets, income statements, etc.) provided as reference materials for shareholders to exercise their voting rights. This aligns with the definition of a Proxy Solicitation & Information Statement (PSI).
2020-02-26 Korean
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for Samchundang Pharm. It outlines the date, location, and agenda items (such as financial statement approval, auditor appointment, and director compensation). This type of document is a standard proxy solicitation/information statement provided to shareholders to inform them of upcoming meeting details and agenda items, fitting the PSI category.
2020-02-18 Korean
기업설명회(IR)개최
Investor Presentation Classification · 98% confidence The document is an official announcement regarding the scheduling and details of an Investor Relations (IR) meeting (기업설명회). It provides the date, location, purpose, and agenda for the meeting. Since this is an announcement of an upcoming event rather than the presentation slides themselves or a full financial report, it falls under the category of a regulatory filing announcement regarding corporate events.
2020-02-04 Korean
현금ㆍ현물배당결정
Notice of Dividend Amount Classification · 100% confidence The document is a formal announcement from Samchundang Pharm regarding the decision to pay cash dividends. It specifies the dividend amount per share, the total dividend amount, the record date, and the expected date of the general meeting for approval. This fits the definition of a 'Notice of Dividend Amount' (DIV).
2020-01-20 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 95% confidence The document is a regulatory filing from a Korean company (Samchundang Pharm) announcing a significant change (over 15%) in revenue or profit structure. This is a standard disclosure requirement for listed companies in Korea (DART system) when financial results deviate significantly from the previous period. Since it provides key financial highlights (revenue, operating profit, net income) before the final audit is completed, it functions as an initial earnings announcement. Among the provided categories, 'Earnings Release' (ER) is the most accurate classification for this type of preliminary financial disclosure. FY 2019
2020-01-20 Korean
주주명부폐쇄기간또는기준일설정
Notice of Dividend Amount Classification · 95% confidence The document is a short regulatory announcement regarding the closure of the shareholder register for the purpose of determining shareholders eligible to vote at the upcoming Annual General Meeting. It does not contain the full report or proxy materials, but rather serves as a formal notice of a corporate action. Given it is a regulatory announcement regarding shareholder rights and meeting preparation, it fits best under the RNS category.
2019-12-16 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.